

# Single Nucleotide Polymorphisms of DNA Methyltransferase 1 Gene and Gastric Cancer in Iranian Patients: a Case Control Study

Khatami F<sup>1</sup>, Noorinayer B<sup>1</sup>, Ghiasi S<sup>1</sup>, Mohebi R, Hashemi M<sup>2</sup>, Zali MR<sup>1</sup>

## Abstract

**Background:** Gastric cancer is one of the most common malignant tumors in Iran. Hypomethylation and/or hypermethylation of DNA have been described in Gastric cancer and is presumed to be an early event in this process.

**Objective:** We hypothesized that Single nucleotide polymorphisms of DNMT1 gene may be associated with the genetic susceptibility to Gastric cancer.

**Methods:** 200 patients and 200 controls, both with Iranian origin were studied. Three polymorphisms were genotyped by PCR-RFLP. Allele frequencies and genotypes were compared between the cases and controls. Odds ratios were calculated and the interaction between polymorphisms, age and sex were examined.

**Results:** There was no significant association between DNMT1 polymorphisms and Gastric cancer.

**Conclusion:** We could not show any association between DNMT1 polymorphisms and gastric cancer. Larger sets of polymorphisms and sample sizes are required to test the possibility of association between polymorphisms of this gene and gastric cancer.

**Keywords:** single nucleotide polymorphisms (SNPs), DNA methyltransferase 1 (DNMT1), gastric cancer (GC)

1. Research Center for Gastrointestinal and Liver Disease, Shahid Beheshti University (MC), Taleghani Hospital.
2. Associate Professor of pathology. Imam Hossein Hospital.

**Corresponding author:**  
Fatemeh Khatami  
Email: [khatam81@yahoo.com](mailto:khatam81@yahoo.com)  
Tel: +982122418872, 22402639  
Fax: +98212402639

IJCP 2008; 3: 111-118

## Introduction

Gastric cancer is a complex disease with both environmental and genetic factors being important in pathogenesis of disorder 1. It is one of the most common cancer in Iran and in most cases occurs in most cases as a sporadic disease in which no single gene with obvious mendelian pattern of inheritance can be identified. It is hypothesized that there is a genetic background that in the presence of other known or unknown environmental factors the risk of gastric cancer in individual patients, can be determined.

The DNA methylation plays a crucial role in transcriptional regulation and chromatin remodeling in mammalian cells 2. Both The DNA hypomethylation and/or regional DNA hypermethylation have been well documented in various tumors 3. Three enzymes, DNA methyl transferase 1 (DNMT1), DNMT3a and DNMT3b 4 have been shown to possess DNA methyltransferase activity 5-9. DNMT1 is required for maintenance of DNA methylation whereas

DNMT3A and DNMT3B are responsible for de novo methylation of DNA 10-12.

Over-expression of DNMT1 has been detected in several human cancers 13, 14 including gastric cancer. Mammalian DNA replication initiates from multiple replication foci targeting region (FTR) during the S phase. Two of these FTRs are located on exon 17 and 20 of the DNMT1 gene 15 so the polymorphisms in FTRs region could be an important factor of DNMT1 alteration.

DNMT1 mRNA is undetectable in growth-arrested cells but is induced upon entrance into the S phase of the cell cycle. The 3'-UTR of the DNMT1 mRNA can confer a growth-dependent regulation on its own message. A 54-nucleotide highly conserved element within the 3'-UTR is necessary and sufficient to mediate this regulation 16, so any modification of 54-nucleotide highly conserved element in 3'-UTR could be an important factor that controls the role of DNMT1 gene products.

The single nucleotide polymorphisms (SNPs) are common allelic variants occurring around once for every 500 to 2000 base pairs in human genome 17. It

**Table 1:** Primer set sequences used for amplification of four SNPs in DNMT gene.

SNP	Forward primer	Reverse primer	Tm
rs721186	5'-CTGGTAGAACATGCCTGATGGTC	5'- TGAACCGCTTCACAGAGGAC	67°C
rs13784	5'- CCCAGGGTGGTTATAGGAGAG	5'-GGCTGACATGAAGCTGGTGCAGGTT	60°C
rs2228611	5'- TATGTTGCCAGGCTCGTCTC	5'- GTACTGTAAGCACGGTCACCTG	63°C
rs11488	5'- CACTGGGTGGTTATAGGAGAGATTCTT	5'- GA TCAAATTGTGCAGTACTTAGTGCATT	62°C

**Table 2:** Restriction enzymes and the resulting RFLP digestion products used for the detection of DNMT gene SNPs.

SNP ID	Restriction Enzyme	PCR product length	Homozygote Wild	Homozygote mutant
rs721186	Acyl	300bp	200bp,200bp	300bp
rs13784	BstAPI	210bp	210bp	27bp,183bp
rs2228611	Alw26I	260bp	232bp,28bp	108bp,124bp,28bp
rs11488	Ddel	162bp	144,28	116,18

**Table 3:** Distribution of genetic polymorphisms of DNMT1 among patients with gastric cancer and the control group in an Iranian population.

		Case	Control	OR(95%CI)
rs721186	Wild/Wild	99(99%)	200 (200%)	1
	Wild/Mutant	1 (1%)	0 (0 %)	1.121(0.06 -16)
rs13784	Wild/Wild	200(200%)	200 (200%)	1
	Wild/Mutant	0(0%)	0 (0%)	0.00 (0.00)
rs2228611	Wild/Wild	34(34%)	32(28%)	1
	Wild /Mutant	50(50%)	62(55%)	1.126 (0.05 - 6.30 )
	Mutant/Mutant	16(16%)	18(16%)	0.836 (0.06 -12.6)
rs11488	Wild/Wild	200 (200%)	200 (200%)	0.00 (0.00)
	Wild/Mutant	0 (0%)	0 (0%)	

OR=odd ratio, CI=confidence interval.

All odds ratios were calculated for odds of Heterozygous against Homozygous genotypes.

is hypothesized that SNPs may determine the genetic susceptibility and/or resistance to different complex disorders including gastric cancer 18. Several polymorphic genes have been associated with modification of susceptibility to gastric cancer 19-21.

To our knowledge, the association between DNMT1 SNPs and risk of gastric cancer development has not been reported yet. In addition, the prevalence of DNMT1 SNPs in Iranian population has not been documented so far. In this study, we examined the hypothesis that the polymorphisms in DNMT1 gene may be associated with gastric cancer. We selected four SNPs of DNMT1 [NCBI Gene ID: 1786] and compared their frequencies between patients with gastric cancer and matched normal controls. Two of selected SNPs, rs2228611 on exon 17 and rs721186 on exon 20, are located in the FTR region, as described above. The other two polymorphisms are located in the 3'-UTR region of DNMT1 mRNA and have been selected to detect their probable effect on growth-dependent regulatory function of DNMT1 gene.

## Materials and Methods

### Patient samples

The study recruited 200 patients with gastric cancer and 200 controls from the biobank of the Research Center for Gastroenterology and Liver Diseases (RCGLD) in Iran. All tumours were pathologically confirmed. Case and controls were matched by age, sex and ethnicity and were selected from the same hospital. At least one control was chosen for every case.

### DNA extraction

Five millilitres of venous blood was collected in vacuum tubes containing EDTA and stored at 4°C. Genomic DNA was extracted within one week of sampling using a standard phenol-chloroform extraction method 22.

### DNMT1 genotyping

The loci for the SNPs rs11488 and rs13784 on 3'-UTR, rs2228611 on exon 17 and rs721186 on exon 20 (in the FTR region of the DNMT1 gene) were amplified by polymerase chain reaction (PCR) (table

**Table 4: Median survival of gastric cancer patients stratified by various factors against SNP 2228611**

<b>A/A Vs A/G and G/G genotypes</b>			
	<b>N</b>	<b>Median survival time (days)</b>	<b>P-value</b>
<b>Gender</b>			
Male	17 vs. 50	1101 vs. 785	0.849
Female	11 vs. 22	1353 vs. 790	0.446
<b>Age at baseline (years)</b>			
≤50	1 vs. 9	-	-
>50	22 vs. 47	496 vs. 790	0.733
<b>Ethnicity</b>			
Fars	8 vs. 24	647 vs. 1200	0.661
Tork	13 vs. 25	1036 vs. 427	0.432
Other	2 vs. 8	457 vs. 440	0.295
<b>Tumor site</b>			
Non-cardiac	21 vs. 63	1036 vs. 790	
Cardiac	6 vs. 9	-	-
<b>Differentiation</b>			
Well and moderate	8 vs. 24	639 vs. 1334	0.319
Poor	4 vs. 18	297 vs. 616	0.216
<b>Cigarette smoking</b>			
Nonsmokers	17 vs. 46	1353 vs. 790	0.611
Smokers	5 vs. 7	528 vs. 828	0.220
<b>Alcohol consumption</b>			
Nondrinkers	22 vs. 62	496 vs. 790	0.484
Drinkers	4 vs. 3	684 vs. 340	0.889

1). The PCR was performed in a final volume of 25  $\mu$ L containing 200 ng of template DNA, 2.5  $\mu$ L of 10X PCR buffer, 1 U of Taq-DNA-polymerase, 200  $\mu$ mol/L of dNTPs and 400 nmol/L of primers. The PCR program consisted an initial denaturation step at 95 °C for 5 min followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 55-67 °C (dependent on the loci) for 30 s, extension at 72 °C for 40 s, and a final step of elongation at 72 °C for 10 minutes. Restriction fragment length polymorphism (RFLP) was used for detection of polymorphisms. The SNPs , restriction enzymes detecting each allele and resulting RFLP digestion products are summarized in table2.

#### **DNA sequencing analysis**

DNA sequence analysis was used to confirm the results of DNMT1 genotyping by PCR-RFLP in 12

randomly selected representative patients. PCR amplicons were first resolved on 1% agarose gels and gel extraction/purification was performed (Promega PCR-clean up system Madison, WI, USA) . Purified products were used as templates in cycle sequencing reactions using dideoxynucleotide chain-termination method ( BigDye Terminator V3.1 cycle sequencing kit Applied Biosystems) . All amplification products were sequenced bi-directionally . ABI PRISM 377 genetic analyzer (applied Biosystems) was used for capillary electrophoresis and data collection.

#### **Statistical analysis**

Allele frequencies were calculated by counting alleles. Goodness of fit between observed and estimated genotype frequencies according to Hardy –Weinberg equilibrium (HWE) was determined by

Table 5: Median survival of gastric cancer patients stratified by various factors

	N	Median survival time (days)	P-value
<b>Gender</b>			
Male	67	496	
Female	33	790	0.5
<b>Age at baseline (years)</b>			
≤50	31	3226	
>50	69	440	0.013
<b>Ethnicity</b>			
Fars	32	790	
Turk	38	433	0.4
Other	28	646	
<b>Tumor site</b>			
Non-cardiac	43	790	
Cardiac	15	684	0.6
<b>Differentiation</b>			
Well and Moderate	32	1036	
Poor	30	558	0.4
<b>TNM pathological (stage)</b>			
I,II	12	1036	
III,IV	65	684	0.3
<b>Treatment</b>			
Surgery	75	1036	
Palliative therapy	25	440	0.1
<b>rs2228611 genotypes</b>			
A/A	30	991	0.646
A/G and G/G	70	1065	
<b>Cigarette smoking</b>			
Nonsmokers	63	790	
Smokers	33	684	0.4
<b>Alcohol consumption</b>			
Nondrinkers	84	790	
Drinkers	7	684	0.5

chi-square test. The observed genotype frequencies were compared with those calculated from Hardy - Weinberg equilibrium theory ( $p^2 + 2pq + q^2 = 1$  where  $p$  is frequency of the variant allele and  $q = 1 - p$ ). In this study, we hypothesized that the presence of the polymorphic allele might be associated with a higher risk of gastric cancer. However, because it was unclear whether the polymorphic allele had a dominant, recessive or gene-dosage effect, statistical modeling was performed on relative risk of the mutant/mutant genotypes or wild/mutant genotypes against wild/wild genotypes, respectively. The ORs and 95% CIs were calculated to estimate the relative risk. All statistical tests were two-sided and performed with Statistical Package for Social Science V.10.0 (SPSS, Chicago, IL).

## Result

The majority of both case and controls were men. Turk and Fars ethnic groups constituted more than 70% of study population. Sixty nine percent of cases were older than 50 compared to 57.7% of controls. Twenty four percent of cases had positive family history of cancer. The most common specified sites for gastric tumours were in Cardia or spanned over two anatomical regions of stomach.

The mean age of the patients was comparable to what in healthy controls ( $50 \pm 13$  vs.  $58 \pm 13$ , respectively;  $P = \text{non significant}$ ). Gender distribution in both groups was similar ( $P = 0.980$ ). Both groups were successfully genotyped for selected polymorphisms (Figure 1). Results for re-genotyped samples were always consistent. Results of PCR-RFLP genotyping were confirmed by direct sequencing

Table 6: Multivariable analysis of prognostic factors in cases

Variables	Risk ratio	P-value
Gender	1.2 (0.57-2.1)	0.67
Age at baseline	1.0 (0.56-2.0)	0.31
Ethnicity	2.7 (0.3-25)	0.38
SNP 2228611 genotypes (A/A vs . A/G, G/G)	1.11 (0.58-2.1)	0.28
Tumor site(Non cardiac vs. Cardiac)	1.3 (0.3-6.0)	0.15
Differentiation (Well/Moderately vs. Poorly /Differentiated)	1.7 (0.1-6.7)	0.22
Smoking	2.1 (0.1-14)	0.63
Treatment type (Surgery vs. Pallivate)	0.1 (0.01-4)	0.07

Table 7: Age and rs2228611 genotypes .

rs2228611	Age	Case	Control	OR	SI
A/A	<50	7	12	1	
A/A	≥50*	23	20	OR A= 1.971	
G/*	<50	18	32	OR G = 0.964	
G/*	≥50*	52	44	OR AG= 2.025	1.065

ORA = ((Cases with Risky Age and Wild/Wild Genotype)/ (Controls with Risky Age and Wild/Wild Genotype))/ ((Cases with Risk less Age and Wild/Wild Genotype)/ (Controls with Risk less Age and Wild/Wild Genotype))

ORG = ((Cases with Risk less Age and Mutant/\* Genotype)/ (Controls with Risk less Age and Mutant/\* Genotype))/ ((Cases with Risk less Age and Wild/Wild Genotype)/ (Controls with Risk less Age and Wild/Wild Genotype))

ORGa = ((Cases with Risky Age and Mutant/\* Genotype)/ (Controls with Risky Age and Mutant/\* Genotype))/ ((Cases with Risk less Age and Wild/Wild Genotype)/ (Controls with Risk less Age and Wild/Wild Genotype))

Synergy Index (SI) = ORGA/ (ORA × ORG)

\*Risky Age

(Figure 1). Genotype distribution in both groups was consistent with what expected by Hardy-Weinberg equilibrium. Distribution of DNMT1 genotypes did not correlate with gender and age in either group. Neither the rs11488 A/T and T/T genotypes nor the G/A and the A/A genotypes of rs13784 were detected in any individual. Both groups were homozygous for the G/G genotype of rs721186 except one person .For rs2228611, the frequencies of A/A, A/G and G/G genotypes in the case and controls were 34% vs. 28%,50% vs. 55% and 16% vs. 16%, respectively ( Table 3 ).The distribution of genotypes and their respective ORs are shown in table 3.

To scrutinize the possible role of rs2228611, we studied the prognostic value of its genotypes by stratifying various clinicopathological parameters of patients (table 4). No specific factor appeared to influence the survival (table5).

Age, sex, ethnicity and stage associations of rs2228611 genotypes with risk of gastric cancer are presented in table 6.

The independent effects of rs2228611 on gastric cancer prognosis were tested in a multivariate analysis model (table5). While being stratified by smoking and family history, distribution of genotypes

did not show any significant difference between two groups.

## Discussion

To our knowledge, this is the first report on an association between the gastric cancer and DNMT1 polymorphisms among Iranian patients. The frequency and degree of DNA hypermethylation were increased in gastric cancer tissue compared with normal mucosa 23, 24 .The same phenomenon has been reported by other groups in the different conditions such as lung cancer, hepatocellular carcinoma, hepatitis and liver cirrhosis25, 26. An increase in DNMT1 mRNA expression level in the gastric cancer in comparison to corresponding noncancerous mucosa was detected 27. It was reported that DNMT1 mRNA overexpression correlates significantly with CpG island methylator phenotype in the gastric and colorectal cancers 28, 29.

The DNMT1 mRNA is regulated by the cell cycle process 30, 31. The DNMT1 mRNA is essentially absent in arrested cells and then increases and reaches its maximum level just before the peak of S phase . The 3'-UTR of DNMT1 confers a growth-dependent regulation on its own mRNA32 .Two of selected SNPs, rs11488 and rs13784, are located in




Figure 1: A) rs2228611 genotyping patterns by PCR-RFLP analysis. B) rs2228611 genotyping patterns by sequencing.

Line 5: PCR product  
 Line 1: RFLP product (homozygote polymorphism)  
 Lines 2, 3, 4, 6, 8: RFLP product (heterozygote)  
 Lines 7, 8: RFLP product (homozygote wild)  
 Line 9: Size marker 200bp

a highly conserved element within the 3'-UTR that is required for mediating the down-regulation of DNMT1 mRNA in arrested cells. We observed no association between these two SNPs and the risk of gastric cancer.

Evidence for the role of DNMT1 in abnormal methylation of genomic DNA in cancers has been contradictory. Despite the assumption that the DNMT1 is responsible for most of the methylation changes observed in cancer cells, it was shown that lack of its activity was associated with a 20% decrease in overall genomic methylation 33. Mammalian DNA replication initiates from multiple sites throughout the S phase. These sites are determined both by cis-acting DNA sequences, known as replicators, and by trans-acting elements, defined by initiator proteins such as DNMT1 that bind to the replicator. The SNPs rs2228611 on exon 17 and rs721186 on exon 20 are placed in replicator recognition region on the DNMT1 gene.

As shown in table 7, older age and the rs2228611 heterozygote genotype have synergistic effect on carcinogenesis. Therefore, the individuals with age more than 50, having A/G or G/G genotypes for SNP 2228611 are more susceptible to gastric cancer. This result should be interpreted cautiously due to lack of consistent findings while we were trying to measure the gene-dosage effects of this polymorphism on the etiogenesis of gastric cancer (table 3). In this study, we could not detect a significant association between the selected DNMT1 polymorphisms and gastric cancer. It is more

desirable to determine the haplotype-tagging polymorphisms of this locus in our population. Genomic association studies performed by selecting and testing the hypotheses of association of the selected tagging polymorphisms with GC may provide more meaningful results. Investigating a complex disorder like gastric cancer, it is also more desirable to consider the role of confounding factors such as environmental factors. These results need to be confirmed by a larger sample size and more polymorphic markers to investigate the true effect of polymorphisms in the DNMT1 locus involved in gastric cancer pathogenesis.

In conclusion, the SNPs rs721186, rs11488 and rs13784 are not associated with the risk of GC. The rs2228611 needs to be studied in a larger sample size.

## Acknowledgements

The authors wish to thank Minoosh Vosoughi, Faramarz Derakhshan and Homayoun Zojaji for their help on data gathering and blood sampling.

## References

1. Laird PW, Jaenisch R. DNA methylation and cancer. *Hum Mol Genet*. 1994; 3 Spec No: 1487-95.
2. Kondo Y, Kanai Y, Sakamoto M, Mizokami M, Ueda R, Hirohashi S. Genetic instability and aberrant DNA methylation in chronic hepatitis and cirrhosis--A comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected

specimens from patients with hepatocellular carcinoma. *Hepatology*. 2000 Nov; 32(5): 970-9.

3. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. *Nat Genet*. 1998; 19(3): 219-20.
4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. *Nat Rev Genet*. 2002 ;3(6): 415-28.
5. Skliris GP, Munot K, Bell SM, Carder PJ, Lane S, Horgan K, et al. Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. *J Pathol*. 2003; 201(2): 213-20.
6. Dincer Y, Akcay T, Celebi N, Uslu I, Ozmen O, Hatemi H. Glutathione S-transferase and O6-methylguanine DNA methyl transferase activities in patients with thyroid papillary carcinoma. *Cancer Invest*. 2002; 20(7-8): 965-71.
7. Niederreither K, Harbers M, Chambon P, Dolle P. Expression of T:G mismatch-specific thymidine-DNA glycosylase and DNA methyl transferase genes during development and tumorigenesis
5. Oncogene. 1998 ;17(12): 1577-85.
8. Wang YM, Wang R, Wen DG, Li Y, Guo W, Wang N, et al. Single nucleotide polymorphism in DNA methyltransferase 3B promoter and its association with gastric cardiac adenocarcinoma in North China. *World J Gastroenterol*. 2005 ; 11(23): 3623-7.
9. Liu K, Wang YF, Cantemir C, Muller MT. Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells *in vivo*. *Mol Cell Biol*. 2003 ;23(8): 2709-19.
10. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell*. 1999 ;99(3): 247-57.
11. Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, et al. De novo CpG island methylation in human cancer cells. *Cancer Res*. 2006 ; 66(2): 682-92.
12. Turek-Plewa J, Jagodzinski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. *Cell Mol Biol Lett*. 2005; 10(4): 631-47.
13. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers 167. *Int J Cancer*. 2001 ; 91(2): 205-12.
14. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis 374. *Hepatology*. 2001 ; 33(3): 561-8.
15. Araujo FD, Knox JD, Ramchandani S, Pelletier R, Bigey P, Price G, et al. Identification of initiation sites for DNA replication in the human dnmt1 (DNA-methyltransferase) locus. *J Biol Chem* 1999 ; 274(14): 9335-41.
16. Detich N, Ramchandani S, Szyf M. A conserved 3'-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity. *J Biol Chem*. 2001; 276(27): 24881-90.
17. Sauer S, Lechner D, Berlin K, Lehrach H, Escary JL, Fox N, et al. A novel procedure for efficient genotyping of single nucleotide polymorphisms. *Nucleic Acids Res*. 2000 ; 28(5): E13.
18. Hemminki K, Forsti A, Lorenzo BJ. Single nucleotide polymorphisms (SNPs) are inherited from parents and they measure heritable events. *J Carcinog*. 2005 ; 4(1): 2.
19. Miao X, Yu C, Tan W, Xiong P, Liang G, Lu W, et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. *Cancer Res*. 2003 ; 63(14): 3987-90.
20. Stolzenberg-Solomon RZ, Qiao YL, Abnet CC, Ratnasinghe DL, Dawsey SM, Dong ZW, et al. Esophageal and gastric cardia cancer risk and folate- and vitamin B(12)-related polymorphisms in Linxian, China. *Cancer Epidemiol Biomarkers Prev*. 2003 ; 12(11 Pt 1): 1222-6.
21. Zhang J, Li Y, Wang R, Wen D, Sarbia M, Kuang G, et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardiac carcinoma in a northern Chinese population. *Int J Cancer*. 2003; 105(2): 281-4.
22. John SW, Weitzner G, Rozen R, Scriver CR. A rapid procedure for extracting genomic DNA from leukocytes 4. *Nucleic Acids Res*. 1991 ; 19(2): 408.
23. Eguchi K, Kanai Y, Kobayashi K, Hirohashi S. DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. *Cancer Res*. 1997 ;57(21): 4913-5.
24. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M, et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas 277. *Int J Cancer*. 1997 ; 71(3): 355-9.
25. Kanai Y, Ushijima S, Ochiai A, Eguchi K, Hui A, Hirohashi S. DNA hypermethylation at the D17S5 locus is associated with gastric carcinogenesis 262. *Cancer Lett* 1998 ; 122(1-2): 135-41.
26. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Hirohashi S. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis 200. *Cancer Lett*. 2000 ;148(1): 73-80.
27. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers 167. *Int J Cancer*. 2001 ; 91(2): 205-12.
28. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers 10. *Am J Pathol* 2004; 164(2): 689-99.
29. Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H, Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis 374. *Hepatology*. 2001 ; 33(3): 561-8.

30. Szyf M, Bozovic V, Tanigawa G. Growth regulation of mouse DNA methyltransferase gene expression. *J Biol Chem* 1991; 266(16): 20027-30.

31. Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. *Nucleic Acids Res* 2000; 28(10): 2108-13.

32. Detich N, Ramchandani S, Szyf M. A conserved 3'-untranslated element mediates growth regulation of DNA methyltransferase 1 and inhibits its transforming activity. *J Biol Chem* 2001; 276(27): 24881-90.

33. Rhee I, Jair KW, Yen RW, Lengauer C, Herman JG, Kinzler KW, et al. CpG methylation is maintained in human cancer cells lacking DNMT1

22. *Nature* 2000; 404(6781): 2003-7